RF Ablation Device with Marker-Targeted Therapeutic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery and radiation therapy, often leave behind residual cancerous cells in the margin tissue around tumor cavities, which can lead to recurrence, and existing methods are costly and have significant side effects.
Innovation Solution
A medical device and method that uses RF ablation to destroy a thin rim of normal tissue around tumor cavities, coupled with the delivery of a therapeutic agent that targets cells with upregulated markers, ensuring complete treatment of diseased cells by preferentially killing those that evade ablation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgery is used to remove tumors, then complete removal and cure is achieved, but residual cancerous cells remain in margin tissue leading to recurrence
Solution Approach 1:
The device performs preliminary ablation of the margin tissue immediately after tumor resection, before residual cancerous cells can regrow. By pre-treating the margin tissue with RF ablation and delivering therapeutic agents that target upregulated markers, the system proactively eliminates potential recurrence sites rather than waiting for cancer to return.
Solution Approach 2:
The device uses upregulated cell surface markers as intermediaries to identify and target residual cancerous cells. The ablation process induces marker upregulation in stressed cancer cells, and the delivered therapeutic agents specifically bind to these markers, creating a targeted delivery mechanism that distinguishes cancer cells from normal margin tissue.
2Object-affected harmful factors
If radiation therapy is used to kill residual cancer cells, then cancer cell destruction is achieved, but treatment cost and side effects increase
Solution Approach 1:
The device extracts and isolates the treatment function to the specific margin tissue region where cancer cells are most likely to recur. By using localized RF ablation and targeted therapeutic delivery rather than whole-body or regional radiation, the system concentrates the anti-cancer effect only where needed, reducing overall treatment complexity and side effects.
Solution Approach 2:
The device applies different treatment modalities to different regions: RF ablation is applied to the immediate margin tissue, while therapeutic agents targeting upregulated markers are delivered preferentially to stressed cancer cells within that same region. This localized, differentiated approach replaces broad radiation therapy with precise, region-specific treatment.
3Reliability
If a thin rim of normal tissue is ablated around the cavity, then residual disease is managed, but normal tissue is damaged
Solution Approach 1:
The system uses marker upregulation as a feedback signal to guide therapeutic delivery. Normal margin tissue that undergoes ablation stress also upregulates markers, but the delivered therapeutics are designed to preferentially target and kill cells with high marker expression (the cancer cells), while sparing normal cells with lower marker levels. This feedback-based discrimination reduces damage to normal tissue.
Solution Approach 2:
The device exploits parameter changes in cell surface marker expression levels to differentiate between cancer and normal cells. After ablation, cancer cells exhibit significantly higher marker upregulation than normal cells. By tuning the therapeutic agent specificity to target these upregulated markers, the system achieves selective cancer cell destruction while preserving normal margin tissue function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively minimizes tumor recurrence by directly killing cancer cells and upregulating cell surface markers, allowing for precise delivery of therapeutics to marginal tissue, thereby ensuring complete clearance of cancerous cells.
Implementation Method 1
The distal portion, including the electrode array, can be delivered to and maneuvered within a tissue cavity (e.g., formed from tumor removal) and configured to ablate marginal tissue (via RF energy) immediately surrounding the tissue cavity
Data Source
AI summary
The present invention is directed to a medical device for providing treatment to diseased tissue and cells. The medical device is configured to ablate a target tissue surface, optionally within a resection cavity, and further deliver a therapeutic that targets diseased (e.g., cancer) cells via a marker whose expression is upregulated by the ablation. The ablation directly kills diseased cells associated with the tissue surface. While some diseased cells evade direct ablation, those cells nevertheless upregulate certain cell surface markers in response to the ablation, even while other, healthy or normal cells do not upregulate expression of the marker in response to the ablation. Devices and methods disclosed herein are used to deliver a therapeutic that uses the upregulated cell surface marker to cause the death of those diseased cells.